Developing the next generation of oncolytic immunotherapy.
RP1 is our first Immulytic™ product to enter the clinic.
We are currently conducting a Phase 1/2 clinical trial in approximately 150 patients with a range of solid tumors in RP1 alone and in combination with nivolumab under a collaboration and supply agreement with Bristol Myers Squibb. In addition, we are preparing to initiate in the first half of 2019 a randomized, controlled Phase 2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in CSCC. This trial is being conducted in collaboration with Regeneron.
RP2 & RP3
RP2 and RP3 are derivatives of RP1 that express additional proteins. RP2 expresses an anti-CTLA-4 antibody-like molecule and RP3 additionally expresses optimized immune co-stimulatory pathway ligands. These therapeutics provide targeted delivery to the sites of immune response initiation in the tumor and draining lymph nodes with the goal of focusing systemic immune-based efficacy on tumors and limiting off target toxicity.